MedTrace Logo

Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)

NCT05966025 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-10-31

No results posted yet for this study

Summary

Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD

Conditions

Interventions

DRUG

Itopride

itopride will be taken by pateints one time per day by dose 100 mg

DRUG

conventional therapy

will taken by patient in control group

Sponsors & Collaborators

  • October 6 University

    lead OTHER

  • Beni-Suef University

    collaborator OTHER

Principal Investigators

  • Hoda m rabea, A Professor · Beni-suaf university

  • Yasmine m madney, Lecturer · Beni-suaf university

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-28
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05966025 on ClinicalTrials.gov